Followers | 13 |
Posts | 1546 |
Boards Moderated | 0 |
Alias Born | 06/14/2018 |
Friday, September 14, 2018 6:17:42 PM
The smaller first, which is easy. Why is TPIV going up and then down and then up and then down?
Because that is what most stocks, markets, commodities, and indexes do over time, the trend may continue up, but they fluctuate down and then back up, etc..
The LARGER issue. I have been reading for months about, when will the merger happen, when will the merger happen, oh if only the merger would happen, we will all be rich when the merger happens, the heavens will open and angels will sing when the merger happens. The stock price will go to $25 or $50 as soon as the merger happens.
Is this the only stock merger that has ever happen?
What happens with most mergers?
No Great, Giant, Huge moves up.
Why? Because it's already priced in to the stock.
That is why you keep hearing, "buy on the rumor, sell on the news".
The pending merger is why TPIV went above $12, up 400% in no time.
Stock dilution normally tends to make a stock price go down.
We will triple the amount of shares, that will make it take off like a rocket??????
IF, IF, IF it does, what should you do?
You already know what I am going to say.
If TPIV shoots up to $25 or $50 as seems to be expected, be smart and PROTECT A PORTION OF YOUR PROFITS by employing staggered trailing stop losses.
WHY? If it shoots up, do you believe it will just continue to shoot up more and then more and then more and be $100+ per share?
In order for that to happen, you need catalysts.
What's the next catalyst after the merger?
When is the next FDA trial info coming out?
I'm sure there will be some institutional money coming in, in November and December JUST SO they can say in their annual report, "Look how smart we were, we owned TPIV and it went up a bunch".
But are they going to throw so much money in after it went from $3 to $25 or whatever that they drive the price up to crazy levels?
Possible, but I seriously doubt it.
History repeats, nature abhors a vacuum, excesses regress to the norm.
This is not a magic stock, TPIV is no different that the 100 other biotechs that merged.
I OWN a good chunk of TPIV, I hope it goes to $50 and then $100 in no time.
Do I expect it? NO.
If it does, am I going to capitalize on that and protect profits?
You betcha.
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM